Clinica Chimica Acta:血液和富血小板血浆检测肺癌

2020-07-19 MedSci原创 MedSci原创

本研究的目的是确定血液和富血小板血浆中的整合血小板特征能否建立肺癌和结肠癌的诊断模型,以及是否可用于区分肺部恶性肿瘤和肺部良性疾病。

本研究的目的是确定血液和富血小板血浆中的整合血小板特征能否建立肺癌和结肠癌诊断模型,以及是否可用于区分肺部恶性肿瘤和肺部良性疾病。

研究人员将245例肺癌患者和86例正常人随机分为训练组和测试组。然后,将32例结肠癌,37例肺癌和21例良性患者纳入验证队列。前瞻性收集所有参与者的全血和相应的富血小板血浆(PRP)样本,并确定血小板特征。在训练队列单变量分析中统计显著的特征和报告的显著特征被输入诊断模型。绘制受试者操作特征(ROC)曲线,以评估模型在每个队列中的准确性。

研究结果显示,在训练队列中,肺癌患者的多种血小板特征有显著差异,包括全血MPV、MPV、PRP中的血小板计数和血小板恢复率(PRR)。在训练队列中,肺癌诊断模型表现良好(AUC = 0.92)。检测队列中肺癌和对照组的概率分布也被诊断模型很好地分离(AUC = 0.79)。结肠癌的诊断模型也表现良好(AUC = 0.79)。该模型在鉴别良性和恶性肺肿瘤方面也具有潜在价值(AUC = 0.69)。

PRR最早被提出并用于肺癌的检测。本研究确定了一种基于全血和PRP样本中PRR和其他血小板特征的诊断模型,有可能将肺癌或结肠癌患者与健康对照者区分开来。该模型还可用于区分肺癌和良性疾病。

原始出处:

RuilingZuSisi YuIntegration of platelet features in blood and platelet rich plasma for detection of lung cancer

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811947, encodeId=737b181194e0c, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Dec 09 12:08:50 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849972, encodeId=927618499e26d, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Sep 10 09:08:50 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340361, encodeId=d09913403617c, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Tue Jul 21 08:08:50 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811947, encodeId=737b181194e0c, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Dec 09 12:08:50 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849972, encodeId=927618499e26d, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Sep 10 09:08:50 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340361, encodeId=d09913403617c, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Tue Jul 21 08:08:50 CST 2020, time=2020-07-21, status=1, ipAttribution=)]
    2020-09-10 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811947, encodeId=737b181194e0c, content=<a href='/topic/show?id=5ab78905623' target=_blank style='color:#2F92EE;'>#血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89056, encryptionId=5ab78905623, topicName=血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Dec 09 12:08:50 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849972, encodeId=927618499e26d, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Sep 10 09:08:50 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340361, encodeId=d09913403617c, content=<a href='/topic/show?id=26bd465e2e3' target=_blank style='color:#2F92EE;'>#富血小板血浆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46572, encryptionId=26bd465e2e3, topicName=富血小板血浆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c932500160, createdName=ms7421025882867189, createdTime=Tue Jul 21 08:08:50 CST 2020, time=2020-07-21, status=1, ipAttribution=)]